Hi @wombat777.
Thank you for your analysis.
You rate a 50% success for AML.
Given the historical success of bisantrene coupled with the recent successful trial in Israel, what are the main outstanding risks that you see remain for Pillar 3?
Is it the risk that the IND will not be approved, and hence no FDA approval?
Or do you think most of the risk is weighted on the clinical side (perhaps unlikely given good historical results)?
Assuming IND is approved, what do you think the success rate would be for pillar 3?
Cheers!
- Forums
- ASX - By Stock
- RAC
- MST valuation of RAC
MST valuation of RAC, page-32
-
- There are more pages in this discussion • 265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
-0.020(1.25%) |
Mkt cap ! $272.6M |
Open | High | Low | Value | Volume |
$1.62 | $1.62 | $1.58 | $68.76K | 43.17K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 193 | $1.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.59 | 757 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 193 | 1.575 |
2 | 829 | 1.570 |
2 | 829 | 1.565 |
1 | 7072 | 1.560 |
1 | 608 | 1.555 |
Price($) | Vol. | No. |
---|---|---|
1.585 | 757 | 1 |
1.590 | 340 | 1 |
1.595 | 86 | 1 |
1.600 | 65000 | 2 |
1.620 | 2623 | 2 |
Last trade - 12.07pm 09/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online